Precigen Financial Results
Precigen reported third quarter 2026 financial results, highlighted by $72.9 million in PAPZIMEOS net revenue, a 37% sequential increase. The company achieved positive cash flow a full quarter ahead of guidance and reported net income of $35.8 million, driven by strong commercial adoption of its RRP treatment.
- Term
- Q3 2026
“Precigen has established an exceptional position of strength, with commercial momentum and a proven strategy driving our next phase of growth. PAPZIMEOS has transformed treatment for adults with RRP, with well over 500 patients initiating treatment and 300 of them having completed treatment demonstrating recognition as the first-line standard of care.”
Helen Sabzevari, PhD, President and CEO of Precigen
“PAPZIMEOS net revenue grew 37% quarter-over-quarter to $72.9 million, demonstrating the strength of our commercial execution and growing demand for the first FDA-approved therapy for adults with RRP.”
Phil Tennant, Chief Commercial Officer of Precigen